Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabazenil SCHEMBL636000 | 1.00 | CNR1 (0.44) | CNR1CNR2MEN1GAAKMT2A | |
| SCHEMBL11816145 | 1.00 | CNR1 (0.44) | CNR1CNR2MEN1GAAKMT2A | |
| Nabazenil SCHEMBL635999 | 1.00 | CNR1 (0.44) | CNR1CNR2MEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL11739184 | 0.99 | CNR1 (0.43) | CNR1CNR2MEN1GAAKMT2A | |
| Nabazenil SCHEMBL11696365 | 0.99 | CNR1 (0.43) | CNR1CNR2MEN1GAAKMT2A | |
| SCHEMBL11808559 | 0.94 | CNR1 (0.43) | CNR1CNR2MEN1GAAKMT2A | |
| SCHEMBL11815877 | 0.93 | CNR1 (0.43) | CNR1CNR2MEN1GAAKMT2A | |
| Bromide SCHEMBL11736990 | 0.93 | CNR1 (0.43) | CNR1CNR2MEN1GAAKMT2A | |
| SCHEMBL11817527 | 0.90 | CNR2 (0.34) | CNR1CNR2 | |
| SCHEMBL11811080 | 0.90 | CNR2 (0.34) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584931-B2 | Devices and cartridges for extracting bio-sample regions and molecules of interest | xMD Diagnostics, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | ANGELES THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12448609-B2 | Heterologous expression of short-chain monooxygenases in microorganisms | INDUSTRIAL MICROBES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4621409-A1 | NOVEL ANTIVIRAL PEPTIDE | Daehannupharm Co., Ltd. (KR) | 2025-09-24 | — | — | EP | disclosed |
| CN-120130607-A | Method for inactivating hybrid bean intracellular lectin by high hydrostatic pressure and mild acid treatment | 华南理工大学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025097015-A1 | CLEC2A-BINDING THERAPEUTICS | FRED HUTCHINSON CANCER CENTER (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12269859-B2 | Synthetic immune receptors and methods of use thereof | ANGELES THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119750936-A | Modified fluorogypsum and preparation method and application thereof | 福建红尖山环保科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119224289-B | Six-color lymph subgroup absolute count freeze-dried pellet and preparation method and application thereof | 江西德普生物技术有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-3502261-B1 | ARTIFICIALLY ENGINEERED ANGIOGENESIS REGULATORY SYSTEM | TOOLGEN INC (KR) | 2025-01-15 | — | — | EP | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115490812-A | Shrinkage-reducing slump-retaining polycarboxylic acid water reducer, and preparation method and application thereof | 江苏诚意工程技术研究院有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-113929837-B | Shrinkage-reducing polycarboxylic acid water reducing agent, and preparation method and application thereof | 同济大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-114956748-A | Polyacrylic acid emulsion modified alkali-activated slag material for repairing and preparation method thereof | 东南大学 | 2022-08-30 | — | — | CN | disclosed |
| US-20220204582-A1 | SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF | ANGELES THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-4012032-A1 | ARTIFICIALLY ENGINEERED ANGIOGENESIS REGULATORY SYSTEM | Toolgen Incorporated (KR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022109684-A1 | ORAL THERAPEUTIC DELIVERY | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-06-02 | — | — | WO | disclosed |
| US-20220135678-A1 | METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES | NATIONAL INSTITUTES OF HEALTH | 2022-05-05 | — | — | US | disclosed |
| CN-114394802-A | Repair mortar for ALC (autoclaved lightweight concrete) board and preparation method thereof | 江苏基策建筑工程有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022056648-A1 | NATURAL SURFACTANTS COMPRISING SOLUBLE NANOCOMPLEXES OF QUINOA PROTEINS/ANIONIC POLYSACCHARIDES (ALGINATE) AND CATIONIC POLYSACCHARIDES (CHITOSAN) FOR USE IN FOODS AND COSMETICS | UNIVERSIDAD DE CHILE (CL) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | NFRKB, NFATC1, NFKBIA | CNR1 2681/4885CNR2 3032/4885MEN1 4802/4885 |
| US-12584931-B2 | Devices and cartridges for extracting bio-sample regions and molecules of interest | CTSL, BCL2L1, CTSV | CNR1 2373/4885CNR2 2177/4885MEN1 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.